BioMark Diagnostics, Inc. · CSE:BUX
BioMark Diagnostics — Investor Presentation (May 2021)
26 slides from BioMark Diagnostics's investor presentation, May 2021

Slide 1: A Next Generation Company Powered by Metabolomics and Artificial Intelligence
A NEXT GENERATION COMPANY POWERED BY METABOLOMICS AND ARTIFICIAL INTELLIGENCE

Slide 2: Our Mission / Who We Are
Our Mission Who We Are Provide better cancer detection, • Developer of a pan cancer liquid biopsy monitoring and screening solutions for platform company with advanced near-to- hard to detect cancers market diagnostic technologies. • Multiple IP’s in detection and quantitation of metabolites. • Hand

Slide 3: BioMark Executive Team & Advisors
BioMark Executive Team & Advisors Rashid Ahmed Bux, MBA Gina Huang, MBA Dr. Bram Ramjiawan, Ph.D Brian Cheng, MSc Founder, Chief Executive Officer CFO and Project Director Clinical Trial and Regulatory Expertise Chief Technical Officer Mr. Alfred Berkeley – Strategic and financial advisor Dr. David

Slide 4: BioMark Corporate Structure
BioMark Corporate Structure 4

Slide 5: Partners & Associations
Partners & Associations Institutions = U of Maryland; Johns Hopkins; Government – CIHR; CHRP; NSERC; Mt Sinai; IUCPQ; University of Manitoba; Genome BC; Canadian Cancer Society University of Alberta; UBC; University of Brescia; Université Laval Japanese based technology company Biopharma – 2 NDAs CR

Slide 6: Value Proposition - Actionable Diagnostic Test
VALUE PROPOSITION- ACTIONABLE DIAGNOSTIC TEST Our technology solution – offers • Early diagnosis and screening – Application in screening for late, aggressive and hard to detect cancers such as lung and Physician Patient brain cancers. These cancers have clearly identified populations. • Effective m

Slide 7: Empowering Oncologists
EMPOWERING ONCOLOGISTS novel technologies for CANCER SCREENING EARLY DETECTION

Slide 8: Lung Cancer – The Big Picture
Lung Cancer – The Big Picture Lung cancer has been the most common cancer in the world for several decades and accounts for 1 in 5 of all cancer deaths. Worldwide, three people die from lung cancer every minute More than 2/3rds of patients are diagnosed with lung cancer at a later stage when their s

Slide 9: 5 Year Relative Survival Rates (%)
5 Year Relative Survival Rates (%) Importance of Stage Shifting – Early Detection is Critical to Save Lives STAGE LUNG (NSCLC) BREAST PANCREATIC 1A 92 100 37 1B 68 2A 60 93 12 2B 53 3A 36 72 3 3B 26 4 10 22 9

Slide 10: Lung Cancer Market Highlights
Lung Cancer Market Highlights Commercialization Roadmap Target - Lung Cancer Screening in US for identified high risk groups to complement LDCT Scan Estimated Population Size : 16 million Current Uptake 3%; 18% cancers detected are indolent; BioMark over diagnosis Imaging is used for Screening – Low

Slide 11: BioMark's Lung Cancer Solution
BioMark’s Lung Cancer Solution Commercialization Roadmap Solution: Use BioMark’s assay that is cost effective and can potentially reduce false positives and negatives associated with LDCT Scans. (reduce and manage diagnostic dilemma) – rule in /out Can use as routine test Following patients with abn

Slide 12: Technology Platform & Product Pipeline
Technology Platform & Product Pipeline Planning Development Validation Regulatory Approval Market Internal Standards developed and data points SSAT-Amantadine Assay using LC/MS –Pan Cancer collected and to be validated. Collaboration with an IVD kit manufacturer begin SSAT-Amantadine Assay using ELI

Slide 13: Discovery & Development of Liquid Biopsy Assays
Discovery & Development of Liquid Biopsy Assays Completed development and validation of 2 metabolomic assays – Platform Play Pan Cancer Acetyl Amantadine Assay (SSAT 1) Multi Panel Biomarkers – First Application Use of an FDA Approved Drug As A Tracer Lung Cancer Based on key discovery by Dr. Sitar

Slide 14: Assay I
Assay I Pan Cancer Acetyl Amantadine Assay (SSAT 1) 14

Slide 15: Convenient & Non-Invasive
Convenient & Non-Invasive SSAT 1 AMANTADINE ASSAY Amantadine + 2 – 4 Hours Water Labs Collect Biological Sample (Urine or Blood) Reference Labs Point of Care Analyze and Confirm Physician Facility or Home (Urine) Physician Report 15

Slide 16: Current SSAT1 Amantadine/Rimantadine Assay Activities
Current SSAT1 Amantadine/Rimantadine Assay Activities Phase III Clinical Trial Use of SSAT 1 Clinical Trial Response to Chemo & Radio For GBM Therapy for Lung Cancer* Urinary Excretion of CancerCare Manitoba The use of SSAT 1 based Acetylamantadine by Cancer biomarkers to assess surgical Patients He

Slide 17: Measuring Response to Treatment for Lung Cancer Using SSAT Assay
Measuring Response to Treatment for Lung Cancer Using SSAT Assay MARKET FOCUS: BioMark’s assay will be used to predict response and outcome of systemic therapy for patients on chemotherapy, immunotherapy and radiotherapy treatment. How ? Determine concurrence to SSAT1 concentration in urine or plasm

Slide 18: Application Leveraging of SSAT Assay – Glioblastoma Market
Application Leveraging of SSAT Assay – Glioblastoma(GBM) Market Activities and Potential Outcomes Our Value Proposition - Develop better diagnostic tools to assess Glioblastoma is the most common primary malignant form of brain progression and response to treatment. No paradigm shift for many cancer

Slide 19: Assay II
Assay II Targeted BioMarker Panel for Early Detection of Lung Cancer Using Liquid Biopsy 19

Slide 20: Targeted Metabolomics Lung Cancer Trials
Targeted Metabolomics Lung Cancer Trials Data Summary Total Subjects: 257 Metabolomics Analysis: Human plasma samples* were analyzed using custom developed assay for several Normal: 60 putative lung cancer biomarkers. Lung Cancer: 197 (emphasis on Stages 1 and 2) *Samples and data obtained from IUCP

Slide 21: Results: Strong AUROC For Early-Stage Detection
Results: Strong AUROC For Early-Stage Detection PERFORMANCE OF LOGISTIC REGRESSION PERFORMANCE OF LOGISTIC REGRESSION MODEL A MODEL B AUC SENSITIVITY SPECIFICITY AUC SENSITIVITY SPECIFICITY TRAINING/ 0.974 (0.965 ~ 0.937 (0.920 ~ 0.922 (0.895 ~ TRAINING/ 0.982 (0.975 ~ 0.960 (0.946 ~ 0.944 (0.921 ~

Slide 22: Next Commercialization Steps for Early Lung Cancer Detection
Next Commercialization Steps for Early Lung Cancer Detection • Sponsored Lung Cancer Trial • Assemble a pan Canadian multidisciplinary team of experts • Source samples from IUCPQ Biobank - (1500 samples) • Timing: April- July 2021 • Set up lab in Quebec for sample analysis -2nd. Quarter 2021 22

Slide 23: Projected Lung Cancer Market Entry & Revenue Model
Projected Lung Cancer Market Entry & Revenue Model ACTIVITY MARKET REVENUE SOURCE TIMING VA L I D AT E M A R K E R S TA R G E T F O R I TA / L D T C E R T I F I C AT I O N AT CANADA-QUEBEC 2021/22 BIOMARK’S LAB IN QUEBEC USING NEW LDTD TECHNOLOGY PROVIDE TEST SERVICE FROM CANADA-QUEBEC SALES OF LD

Slide 24: Impending Catalyst – Short Terms
Impending Catalyst – Short Terms Lung Cancer GBM – Leverage SSAT Platform Set operations in Quebec to accelerate Obtained Health Canada No Objection Letter for commercialization efforts. Secure soft landing GBM trials at CancerCare Manitoba. Patient support fund in 2021 recruitment underway. Study f

Slide 25: BioMark Cap Table Summary
BioMark Cap Table Summary • Trading Symbols: CSE: BUX / OTCMKTS: BMKDF / FSE: 20B • Common Shares Issued and Outstanding: 76,784,229 • Warrants (@ $0.20 & @ $0.45): 2,337,579 • Options (@ $0.15 - $0.30): 4,195,000 • Insiders ownership: 60% • Capital Raised (to-date): CAD $ 11 m 25

Slide 26: Contact Details
Rashid Bux Contact Details rahmed@biomarkdiagnostics.com Rashid.biomark@gmail.com Office: 604-370-0779 Mobile:604-836-6950 www.biomarkdiagnostics.com A NEXT GENERATION COMPANY POWERED BY METABOLOMICS AND 26 ARTIFICIAL INTELLIGENCE
Source: Internet Archive copy of biomarkdiagnostics.com
More decks from BioMark Diagnostics, Inc.
Investor Presentation (September 2025)23 slides · September 2025
Investor Presentation (April 2023)42 slides · April 2023
Investor Presentation (July 2022)33 slides · July 2022
Investor Presentation (June 2019)32 slides · June 2019
Investor Presentation (June 2016)23 slides · June 2016
Investor Presentation (July 2015)25 slides · July 2015